RYTM
リズム・ファーマシューティカルズ
RYTM
リズム・ファーマシューティカルズ
Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Rhythm Pharmaceuticals is transitioning from a single rare disease drug to a broad MC4R therapeutic franchise, leveraging multiple formulations for market segmentation. IMCIVREE's AHO approval and ove
Rhythm Pharmaceuticals NASDAQ: RYTM is expanding commercialization of its rare-disease obesity treatment IMCIVREE while advancing additional melanocortin-4 receptor, or MC4R, agonists through developm
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) b
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)